GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OSE Immunotherapeutics SA (XPAR:OSE) » Definitions » Current Deferred Revenue

OSE Immunotherapeutics (XPAR:OSE) Current Deferred Revenue : €0.00 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is OSE Immunotherapeutics Current Deferred Revenue?

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

OSE Immunotherapeutics's current deferred revenue for the quarter that ended in Dec. 2023 was €0.00 Mil.

OSE Immunotherapeutics Current Deferred Revenue Historical Data

The historical data trend for OSE Immunotherapeutics's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OSE Immunotherapeutics Current Deferred Revenue Chart

OSE Immunotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OSE Immunotherapeutics Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

OSE Immunotherapeutics Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of OSE Immunotherapeutics's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

OSE Immunotherapeutics (XPAR:OSE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OSE Immunotherapeutics SA (XPAR:OSE) » Definitions » Current Deferred Revenue
Comparable Companies
XPAR:ADOC XPAR:MAAT XPAR:ALSEN XPAR:ALVAL XPAR:ALCLS XPAR:ALACT XPAR:TNG XPAR:ABNX XPAR:GNFT XPAR:ALGEN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
6OP:Germany
Address
22, Boulevard Benoni Goullin, Nantes, FRA, 44200
Website
http://www.ose-immuno.com
OSE Immunotherapeutics SA is a France-based biotechnology company focused on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. The product portfolio of the company comprises Tedopi, OSE-172, OSE-703, FR104 and OSE-127.

OSE Immunotherapeutics (XPAR:OSE) Headlines

No Headlines